DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 214 filers reported holding DENALI THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $370,515 | -30.1% | 17,960 | +0.1% | 0.00% | -25.0% |
| Q2 2023 | $529,705 | +129412.2% | 17,950 | +1.1% | 0.00% | +33.3% |
| Q1 2023 | $409 | -17.9% | 17,758 | -0.9% | 0.00% | -25.0% |
| Q4 2022 | $498 | -99.9% | 17,918 | 0.0% | 0.00% | -20.0% |
| Q3 2022 | $544,000 | +3.8% | 17,918 | +0.6% | 0.01% | 0.0% |
| Q2 2022 | $524,000 | +523.8% | 17,816 | +581.0% | 0.01% | +400.0% |
| Q1 2022 | $84,000 | -36.4% | 2,616 | -32.1% | 0.00% | 0.0% |
| Q4 2021 | $132,000 | -57.4% | 3,851 | -37.3% | 0.00% | -50.0% |
| Q3 2021 | $310,000 | -36.2% | 6,146 | -0.8% | 0.00% | -33.3% |
| Q2 2021 | $486,000 | +35.4% | 6,194 | -1.6% | 0.00% | +50.0% |
| Q1 2021 | $359,000 | -26.6% | 6,294 | +7.7% | 0.00% | -33.3% |
| Q4 2020 | $489,000 | +425.8% | 5,844 | +125.6% | 0.00% | +200.0% |
| Q3 2020 | $93,000 | +416.7% | 2,590 | +240.8% | 0.00% | – |
| Q2 2020 | $18,000 | +125.0% | 760 | +65.2% | 0.00% | – |
| Q1 2020 | $8,000 | – | 460 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 5,960,732 | $122,969,901 | 14.32% |
| ARCH Venture Management, LLC | 693,749 | $14,312,042 | 9.30% |
| Flagship Pioneering Inc. | 2,619,968 | $54,049,940 | 3.92% |
| Casdin Capital, LLC | 1,300,000 | $26,819,000 | 2.97% |
| Yiheng Capital Management, L.P. | 1,150,684 | $23,738,611 | 1.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 154,000 | $3,172,400 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 254,941 | $5,259,433 | 1.02% |
| Temasek Holdings (Private) Ltd | 6,895,992 | $142,264,315 | 0.85% |
| Clarius Group, LLC | 378,262 | $7,803,545 | 0.74% |
| Artal Group S.A. | 802,899 | $16,564 | 0.71% |